Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ambroxol decreases bronchial hyperreactivity.

G Melillo, G Cocco

    European Journal of Respiratory Diseases
    |November 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Ambroxol significantly reduces bronchial hyperreactivity in asthma patients by increasing phosphatidylcholine secretion. This new compound more than doubled the methacholine PD20 compared to placebo.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    What is the Functional Role of Obturator Externus Muscle? The Case of a Moderate Tear in a Professional Soccer Player: A Case Report.

    Malaysian orthopaedic journal·2026
    Same author

    Gallbladder polyps ultrasound: what the sonographer needs to know.

    Journal of ultrasound·2021
    Same author

    Sonographic demonstration of a spontaneous rectus sheath hematoma following a sneeze: a case report and review of the literature.

    Journal of ultrasound·2020
    Same author

    Not all abolished lung sliding are pneumothorax: the case of a particular lung atelectasis.

    Journal of ultrasound·2020
    Same author

    The Oxidative Stress-Induced miR-200c Is Upregulated in Psoriasis and Correlates with Disease Severity and Determinants of Cardiovascular Risk.

    Oxidative medicine and cellular longevity·2020
    Same author

    Ultrasound and hepatic abscess: A successful alliance for the internist.

    European journal of internal medicine·2019
    Same journal

    Microbiological studies of tracheostomy site wounds.

    European journal of respiratory diseases·1987
    Same journal

    The effect of a peptide aldehyde reversible inhibitor of elastase on a human leucocyte elastase-induced model of emphysema in the hamster.

    European journal of respiratory diseases·1987
    Same journal

    Procoagulant activities in human alveolar macrophages.

    European journal of respiratory diseases·1987
    Same journal

    Occurrence of breathing problems induced by cold climate in asthmatics--a questionnaire survey.

    European journal of respiratory diseases·1987
    Same journal

    Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy.

    European journal of respiratory diseases·1987
    Same journal

    The effect of cigarette withdrawal on asthmatics who smoke.

    European journal of respiratory diseases·1987
    See all related articles

    Area of Science:

    • Pulmonology
    • Pharmacology

    Background:

    • Ambroxol, a novel compound, enhances phosphatidylcholine secretion by type II pneumocytes.
    • Phosphatidylcholine secretion may modulate bronchial hyperreactivity by affecting lysophosphatidylcholine turnover and airway secretion layers.

    Purpose of the Study:

    • To investigate the effect of ambroxol on bronchial hyperreactivity in asthmatic patients.

    Main Methods:

    • A double-blind, cross-over study was conducted with 11 asthmatic patients.
    • Patients received either 90 mg of ambroxol or placebo orally for 14-day periods.
    • Methacholine provocative dose 20 (PD20) was assessed before and after each treatment period.

    Main Results:

    • Ambroxol significantly increased mean methacholine PD20, more than doubling the effect observed with placebo.

    Related Experiment Videos

  • Ambroxol demonstrated a significant increase in baseline PD20 values, indicating reduced bronchial hyperreactivity.
  • Placebo administration did not result in a significant change in bronchial hyperreactivity.

    • Conclusions:

    • Ambroxol effectively reduces bronchial hyperreactivity in asthmatic individuals.
    • The compound's mechanism may involve increased phosphatidylcholine secretion.
    • Ambroxol presents a promising therapeutic option for managing asthma-related bronchial hyperreactivity.